KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study

Simone Ferrero, Davide Rossi, Andrea Rinaldi, Alessio Bruscaggin, Valeria Spina, Christian W. Eskelund, Andrea Evangelista, Riccardo Moia, Ivo Kwee, Christina Dahl, Alice Di Rocco, Vittorio Stefoni, Fary Diop, Chiara Favini, Paola Ghione, Abdurraouf Mokhtar Mahmoud, Mattia Schipani, Arne Kolstad, Daniela Barbero, Domenico Novero, Marco Paulli, Alberto Zamò, Mats Jerkeman, Maria Gomez da Silva, Armando Santoro, Annalia Molinari, Andres Ferreri, Kirsten Grønbæk, Andrea Piccin, Sergio Cortelazzo, Francesco Bertoni, Marco Ladetto, and Gianluca Gaidano

Disclosures: DR: Honoraria (Abbvie, Gilead, Janssen, Roche), Research Grant (Abbvie, Gilead) All the other Authors have no conflict of interests to declare. GG: Advisory board (Abbvie, Janssen), Honoraria (Astra-Zeneca, Sunesys)

Contributions: DR, SC, FB, ML and GG designed and performed research; SF, DR, ADR, ViSt, PG, MGdS, AS, AM, AF, AP, SC, ML and GG enrolled patients; SF, DB, DN, MP, ML and AZ provided biological samples SF, DR, AR, AB, VaSp, IK, FD, CF and DB performed research; SF, DR, AR, AB, VaSp, AE, RM and IK analysed data; CWE, CD, AK, MJ and KG provided data for the validation; SF, DR, AE, RM, FB, ML and GG wrote the paper. The authors would like to thank all the patients who participated in the study. We are grateful to Gian Maria Zaccaria, Marco Ghislieri, Paola Ghione and Andrea Piccin (Department of Hematology, Ospedale Generale, Bolzano, Italy) for their scientific advice and to Luigia Monitillo, Antonella Fiorillo, Antonella Ferranti and Daniela Gioia for their assistance.